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A b s t r a c t
Introduction: The aim of the study was to devise a  strategy to diagnose 
malign endometrial pathologies (adenocarcinoma or atypical hyperplasia) 
that minimizes the number of invasive tests done (hysteroscopy, aspiration 
biopsy or curettage) with no loss of its detection efficiency.
Material and methods: We retrospectively studied the clinical histories 
of 779 postmenopausal women at the University Hospital Complex of Al-
bacete, for whom an endometrial study had been done (hysteroscopy, aspi-
ration biopsy or curettage) with a 1-year follow-up between 1 March 2006 
and 31 March 2008. 
Results: There were 77 cases of a malignant pathology (66 adenocarcino-
mas and 11 hyperplasias with atypia); 96.1% had metrorrhagia, and there 
were only 3 cases of asymptomatic patients (all 3 presented endometrial 
thickness of > 5 mm: 10, 12 and 15 mm). The sensitivity and specificity of 
the transvaginal ultrasound, with a 5 mm cut-off point to diagnose a ma-
lignant pathology, were 98.4% and 30.1%, respectively; 89.1% and 99.6%, 
respectively, for aspiration biopsy; 83.9% and 99.1%, respectively, for hys-
teroscopy without biopsy; and both were 100% for biopsy. Statistical signif-
icance was considered at p < 0.05 and confidence intervals were calculated 
at 95%. 
Conclusions: In postmenopausal women with metrorrhagia, the first action 
to take is to do a transvaginal ultrasound, followed by en endometrial study, 
but only if the endometrium is irregular or endometrial thickness is ≥ 5 mm; 
in asymptomatic women, the cut-off point should be set at 10 mm. The im-
mediate method of choice is an ambulatory biopsy.
Key words: adenocarcinoma, aspiration biopsy, metrorrhagia, hysteroscopy, 
ultrasound.
Introduction
Endometrial adenocarcinoma is the most frequent feminine tumor of 
the lower genital tract in developed countries. It is 40% more frequent 
than ovarian cancer, more than double the number of cervical cancer cas-
es, and it has the highest frequency after breast, colon and lung cancer 
[1]. Abnormal uterine bleeding is the presenting symptom in 75–90% of 
cases. The majority of patients with endometrial cancer are diagnosed 
with no evidence of extrauterine spread (70–80% stage I), which gives 
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patients a  better prognosis. In more advanced 
disease the sites commonly affected outside the 
uterus are pelvic and para-aortic lymph nodes 
and the ovaries. Although not usual, it has also 
been described in bone metastases [2]. Given 
its frequency, we decided to look for a strategy 
to diagnose it by minimizing the invasive tests 
done on the endometrium, but without loss of 
reliability of diagnoses of the malign endometri-
al pathology, by considering both adenocarcino-
ma and hyperplasia with atypia.
A transvaginal ultrasound is a less invasive test 
and proves quite useful when having to discrim-
inate cancer or hyperplasia depending on endo-
metrial thickness in a postmenopausal patient [3]. 
It is a valid preliminary test in patients with met-
rorrhagia, and those who obtain a positive result 
in it (endometrial thickness values of 4–5 mm, 
according to some authors [4]) should undergo 
more invasive studies, such as a hysteroscopy or 
an endometrial biopsy [4, 5]. Finally, a diagnostic 
curettage [6] should be employed only for special 
cases in which the performance of the previous 
tests is not feasible. 
Material and methods
Patients studied
We carried out a descriptive, cross-sectional ret-
rospective study of 779 postmenopausal patients 
who were submitted to an endometrial study, de-
fined by performing diagnostic hysteroscopy and/
or histological study, with a 1-year follow-up in the 
University Hospital Complex of Albacete between 
1 March 2006 and 31 March 2008.
Procedures
We have created two large diagnostic group: 
1)  Malign pathology: includes cases of adenocarci-
noma or hyperplasia with atypia.
2)  Malign and precursor pathology: includes group 
1 (cases of adenocarcinoma or hyperplasia with 
atypia) and hyperplasia without atypia. 
An ambulatory biopsy is done during the con-
sultation, which requires no preparation by the 
patient, by introducing a Cornier cannula through 
the cervix to obtain a sample by aspiration. 
A diagnostic curettage is performed surgically 
with general anesthetic after hospitalizing the pa-
tient. 
An ambulatory diagnostic hysteroscopy is car-
ried out in the hospital’s Diagnostic Hysteroscopy 
Unit using oral analgesia and diazepam. Depend-
ing on the findings, an assisted biopsy is carried 
out, or not. On occasion, a  blind biopsy is done 
with a  Cornier or a  Novak cannula to finish the 
technique if we consider that an assisted biopsy 
does not suffice. 
Data collection
To carry out this study, two databases were 
used: the diagnostic hysteroscopy database and 
the anatomic pathologic database. After consid-
ering the inclusion criteria (being postmenopaus-
al and having undergone all the supplementary 
tests in our center) and the exclusion criteria (not 
having access to clinical histories and not having 
a definite diagnosis) with all the patients, 595 di-
agnostic hysteroscopies with or without assisted 
biopsy and 322 endometrial biopsies (305 aspira-
tion biopsies and 17 curettages) were carried out. 
Some patients had more than one test done. In all, 
779 patients were studied. 
After completing patient selection, we collected 
the data of the procedures done (aspiration biop-
sy, diagnostic hysteroscopy and curettage) and the 
diagnosis received. After for a year, we related it to 
the retrospective clinical data (collected from their 
clinical histories) to find a  connection, as these 
data were those that motivated us to do this study.
Statistical analysis
The association between the qualitative variables 
was assessed using a Pearson χ2 test by calculating 
the odds ratios (ORs) with their 95% confidence in-
tervals (CI). To adjust risks for possible confounding 
variables, we did a multivariate analysis by non-con-
ditional logistic regression. When calculating the 
sensitivity and specificity of the tests employed, the 
following cut-off points were considered for their 
positivity: transvaginal ultrasound, for which we set 
the cut-off point for endometrial thickness mea-
sured longitudinally as being greater than or equal 
to 5 mm; ambulatory biopsy, for which we set two 
cut-off points: firstly, we considered the adenocarci-
noma or hyperplasia with atypia results to be a pos-
itive biopsy; secondly, we considered the adeno-
carcinoma or hyperplasia with and without atypia 
results to be a positive biopsy; diagnostic hysteros-
copy, for which we set two cut-off points: firstly, we 
evaluated the diagnostic capacity of a hysteroscopy 
to diagnose a malign pathology by considering an 
image suggestive of adenocarcinoma to be positive; 
secondly, we evaluated the diagnostic capacity of 
a hysteroscopy to diagnose a malign pathology by 
considering an image suggestive of adenocarcino-
ma or hyperplasia to be positive.
For the ratios, 95% confidence intervals were 
calculated by the Fisher method with the OpenEpi 
program. Statistical significance was considered 
to be p < 0.05, and all the confidence intervals 
were calculated at 95%.
Results
The diagnoses made after performing the study 
are presented in Table I. 
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Transvaginal ultrasound
The sensitivity of the transvaginal ultrasound 
for adenocarcinoma by using a  endometrial 
thickness cut-off point of 5 mm was 98.4%, and 
its specificity was 30%. For malign pathology (ad-
enocarcinoma or hyperplasia with atypia), these 
values rose slightly to 98.7% and 30.1%, respec-
tively. Finally for malign or precursor pathology, 
the values obtained were 95% and 32.2%, re-
spectively. 
Table II describes the ratio of the transvaginal 
ultrasound findings depending on the pathology 
diagnosed. 
Further transvaginal ultrasound information to 
be considered is the presence of intracavity fluid, 
as of the 16 patients who presented it, 8 (50%) 
were diagnosed as having adenocarcinoma.
We selected the cases of patients who present-
ed metrorrhagia, which we related to the scan 
findings and the definite diagnoses at the end of 
the study. We found no case of malignant pathol-
ogy among the patients with a  regular atrophic 
endometrium (95% CI: 0–2.6), and there was only 
1 adenocarcinoma case among the 33 patients 
with an irregular atrophic endometrium (3%; 
95% CI: 0.07–15.7). 
Among the asymptomatic patients, only 3 cases 
of malignant pathology were found, with a hyper-
trophic endometrium in them all (2 adenocarci-
nomas with endometrial thickness (ET) of 12 mm 
and 15 mm, and 1 hyperplasia with atypia and ET 
of 10 mm). 
Aspiration biopsy 
The results of the 305 aspiration biopsies per-
formed are presented in Table III. To study the 
diagnostic capacity of an aspiration biopsy, we 
set two cut-off points for the biopsy result to be 
considered positive: cut-off point 1 was the ad-
enocarcinoma or hyperplasia with atypia results 
considered to be a positive biopsy. Using this cut-
off point to diagnose a malignant pathology, the 
sensitivity and specificity values of the aspiration 
Table I. Definite diagnosis of the 779 studied pa-
tients
Definite diagnosis Number Percentage
Normal† 331 42.5
Benign pathology# 306 39.3
Hyperplasia without atypia 65 8.3
Hyperplasia with atypia 11 1.4
Adenocarcinoma 66 8.5
†Atrophic endometrium, weakly proliferative endometrium, 
secondary endometrial changes to treatment, septate uterus or 
endometrial adherences. #Polyp or myoma.
Table II. Proportion of all the transvaginal ultrasound findings according to the pathology diagnosed
Transvaginal ultrasound finding† AC
(n = 66)
HWA
(n = 11)
HNA
(n = 63)
BP
(n = 295)
Normal
(n = 312)
E. Regular atrophy 0 0 0 13 136
E. Irregular atrophy 1 0 6 25 22
E. Regular hypertrophy 9 4 19 67 102
E. Irregular hypertrophy 56 7 38 190 52
†We have 747 transvaginal ultrasound findings of all the 779 patients included in this study. AC – adenocarcinoma, HWA – hyperplasia with 
atypia, HNA – hyperplasia with no atypia, BP – benign pathology (polyp or myoma), Normal – weakly proliferative atrophic endometrium 
with secondary changes to treatment, adherences or septate uterus.
Table III. Relation between the results of the aspiration biopsy and the definite diagnosis
AB results Definite diagnosis at the end of the study
Normal BP HNA HWA AC Total
IS 49 20 5 0 2 76
Normal 135 28 6 1 0 170
BP 0 7 3 1 0 11
HNA 0 1 4 0 1 6
HWA 1 0 0 0 1 2
AC 0 0 0 0 40 40
Total 185 56 18 2 44 305
AB – aspiration biopsy, Normal – weakly proliferative atrophic endometrium or with secondary changes to treatment, BP – benign pathology 
(polyp or myoma), HNA – hyperplasia with no atypia, HWA – hyperplasia with atypia, AC – adenocarcinoma, IS – insufficient sample.
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biopsy were 89.1% (95% CI: 76.96–95.27) and 
99.6% (95% CI: 97.85–99.93), respectively, with 
a positive predictive value of 97.6% (95% CI: 87.6–
99.58) and a negative predictive value of 98.1% 
(95% CI: 95.63–99.19). 
The biopsy diagnosed the only case of adeno-
carcinoma in a patient who presented an irregular 
atrophic endometrium in the scan and metrorrha-
gia. Cut-off point 2 was the adenocarcinoma and 
hyperplasia (with and without atypia) results con-
sidered to be a positive biopsy. Using this cut-off 
point to diagnose a malignant or precursor pathol-
ogy, the sensitivity and specificity values of the as-
piration biopsy were 71.8% (95% CI: 59.87–81.45) 
and 99.1% (95% CI: 97.03–99.77), respectively, 
with a positive predictive value of 95.83% (95% CI: 
86.02–98.85) and a  negative predictive value of 
93% (95% CI: 89.2–95.52).
Hysteroscopy
We performed 595 hysteroscopies, and the ob-
tained results are provided in Table IV. To study the 
diagnostic capacity of the hysteroscopy, we set 
two cut-off points where the hysteroscopy result 
is considered positive: cut-off point 1: we evaluat-
ed the diagnostic capacity of the hysteroscopy to 
diagnose a malignant pathology by considering an 
image suggestive of adenocarcinoma to be posi-
tive. The sensitivity and specificity of the hysteros-
copy without assisted biopsy to diagnose a malig-
nant pathology were 64.3% (95% CI: 48.0–78.4%) 
and 99.3% (95% CI: 98.2–99.8) respectively, with 
a positive predictive value of 87% (95% CI: 70.1–
96.3) and a  negative predictive value of 97.3% 
(95% CI: 95.3 and 98.5). Cut-off point 2: we eval-
uated the diagnostic capacity of the hysteroscopy 
to diagnose a malignant pathology by considering 
an image suggestive of adenocarcinoma or hyper-
plasia to be positive. The sensitivity and specific-
ity of the hysteroscopy without assisted biopsy 
to diagnose a  malignant pathology were 92.8% 
(95% CI: 80.5–98.5%) and 73.6% (95% CI: 69.9–
77.1%), respectively, with a positive predictive val-
ue of 24.8% (95% CI: 18.3–32.3) and a negative 
predictive value of 99.3% (95% CI: 98.1–99.8).
Diagnostic curettage
We carried out this procedure in 17 patients, of 
whom 7 had adenocarcinoma and were correctly 
diagnosed by curettage. The results have a limita-
tion due to the small sample size. 
Discussion
Most of the patients diagnosed with a malig-
nant pathology included in our study had come to 
consultations for metrorrhagia. The first step was 
to do a  transvaginal ultrasound, where we ob-
served, except for 1 patient with an irregular atro-
phic endometrium, that the remaining patients 
with a  malignant pathology presented hypertro-
phic endometrium. The high aspiration biopsy 
sensitivity obtained to diagnose a malignant pa-
thology allowed us to employ this diagnostic test 
as a  first study step after performing the trans-
vaginal ultrasound. In those cases in which the 
diagnosis was doubtful, diagnostic hysteroscopy 
with an assisted biopsy provided 100% sensitivity 
when detecting a malignant pathology. 
The strong point of this study lies in the large 
number of patients studied and the homogeneous 
vision of the hysteroscopy specialists and pathol-
ogists, as the same specialists always performed 
the same techniques. 
The study limitations are mainly due to its 
retrospective nature which made data organiza-
tion a difficult task because some data were not 
available for all the patients. Furthermore, when 
analyzing the diagnostic techniques performed, 
the sample was not homogeneous because there 
were many more patients who had undergone 
a  diagnostic hysteroscopy than those who had 
been referred for an ambulatory biopsy or curet-
tage. 
Table IV. Relation of the hysteroscopy findings and the definite diagnosis
HSC results Definite diagnosis at the end of the study
Normal BP HNA HWA AC Total
Normal 182 1 0 0 0 183
Benign-looking polyp 0 221 17 3 0 241
Myoma 0 14 0 0 0 14
Hyperplastic E. or P. 7 65 42 7 5 126
AC 0 1 3 1 26 31
Total 189 302 62 11 31 595
HSC – hysteroscopy, Normal – weakly proliferative atrophic endometrium or with secondary changes to treatment, BP – benign pathology 
(polyp or myoma), HNA – hyperplasia with no atypia, HWA – hyperplasia with atypia, AC – adenocarcinoma, E – endometrium, P – polyp.
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Transvaginal ultrasound
This technique is a less invasive test and proves 
quite useful when having to discriminate cancer or 
hyperplasia depending on endometrial thickness 
in a postmenopausal patient, and it is valid as an 
initial test in patients with metrorrhagia [7]. If its 
result is positive (ET values between 4 mm and 
5 mm, according to some authors) [4, 8, 9], per-
forming a hysteroscopy is recommended [10, 11]. 
The meta-analysis of Smith-Bindman et al. [12] 
with postmenopausal women reported that 96% 
of women with a malignant endometrial pathology 
and 92% of those with some endometrial disorder 
presented an ET over 5 mm and that the specificity 
for endometrial cancer with this cut-off point was 
68%. Our results coincide with these data. 
In the asymptomatic patients, several studies in-
dicate that a transvaginal ultrasound is not a good 
screening method [13–15]. A good cut-off point to 
conduct further studies in postmenopausal patients 
would be 10 mm based on our results and as com-
pared with those reported by other authors [16]. 
Aspiration biopsy
The clinical guidelines of the Royal College of 
Obstetricians and Gynaecologists (RCOG) [17] 
contemplates that endometrial biopsy sensitivity 
in postmenopausal women who do not present an 
endometrial pathology is lower, probably due to 
endometrial atrophy, as we verified in our results: 
for 26.4% of the women presenting atrophic en-
dometria, the sample collected by an ambulatory 
biopsy proved insufficient to make a diagnosis. If 
cancer had been present, this probability of fail-
ure to obtain a sample would be markedly lower. 
The false-negative rate for endometrial cancer for 
these patients was very low and could, therefore, 
be excluded (sensitivity and specificity of 99.6% 
and 91.0%, respectively [18]). In general, further 
cavity evaluation should be made if symptoms 
persist or recur, or if structural endometrial anom-
alies are suspected [17].
The false negatives in our study were basically 
due to lesions on polyps. Despite the endometri-
al biopsy being a useful and inexpensive test to 
identify endometrial malignancy and premalig-
nancy, it is a  poor test to diagnose endometrial 
structural anomalies such as submucous polyps 
and myoma [18]. 
Thus, we consider that the ambulatory biopsy 
offers high sensitivity in homogeneous hypertro-
phic endometria, but lower sensitivity in non-ho-
mogeneous cases. Our recommendation, which 
coincides with that made by other authors [19], is 
to immediately perform an aspiration biopsy with 
patients with postmenopausal metrorrhagia and 
hypertrophic endometria (irrespectively of them 
being homogeneous or not), and also in post-
menopausal patients who do not present metror-
rhagia, but an endometria of ≥ 10 mm, because it 
is a  simpler, less awkward technique with fewer 
complications than a diagnostic hysteroscopy. We 
would resort to a hysteroscopy only if the result 
was not a malignant pathology, and despite our 
suspicions, in order to continue the study.
Hysteroscopy
The range of overall hysteroscopy sensibility is 
92–97%, and the false negatives obtained are at 
the expense of an endometrial hyperplasia [20], 
as in our study, and an assisted endometrial biop-
sy is always indicated whenever in doubt. Other 
authors offer studies with a sensitivity and spec-
ificity value of the hysteroscopy image to predict 
endometrial cancer of 50.0% and 99.5%, respec-
tively, and they state that a hysteroscopy must al-
ways accompany an endometrial biopsy because 
an image alone is not sensitive enough to speci-
fy whether we are faced with a malign or benign 
process [21]. Bedner and Rzepka-Górska calculat-
ed the sensitivity of diagnosis in a hysteroscopic 
image of several lesions [22]. The agreement of 
the macroscopic image with the anatomo-patho-
logical report was variable according to lesion 
type, with 90.9% in submucous myoma, 86.9% in 
endometrial polyps, 25.0% in endometrial hyper-
plasia and 71.4% in endometrial carcinoma cases. 
This author concluded that the hysteroscopic vi-
sion was not sufficient to diagnose a malignant or 
premalignant pathology. Hence taking an assisted 
biopsy would always be indicated, as we have ver-
ified with our results.
Hysteroscopy specificity for endometria with 
no pathology (atrophic, weakly proliferative or 
with secondary changes to treatment) was 99.7%, 
which is similar to that which has been reviewed 
[21]. The RCOG recommends performing biopsies 
even with a normal hysteroscopy [17]. Nowadays, 
it is recommended to combine a  hysteroscopy 
with biopsies if a scan finds that the endometri-
um is over 4 mm, and to carry out curettage of the 
cavity if malignancy is suspected despite a normal 
hysteroscopy image [17].
In conclusion, the study of a postmenopausal 
patient with metrorrhagia must begin by doing 
a  transvaginal ultrasound and performing other 
tests in accordance with the endometrial thick-
ness found. We consider it correct to continue the 
study if faced with irregular endometria or endo-
metrial thickness of ≥ 5 mm as a first option by an 
ambulatory biopsy, and by a diagnostic hysteros-
copy if in doubt.  
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